
Sign up to save your podcasts
Or


In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
By American Society of Hematology4.1
4949 ratings
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles

11,155 Listeners

139 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,156 Listeners

2 Listeners

363 Listeners

372 Listeners

1 Listeners

48 Listeners

189 Listeners

30 Listeners

4 Listeners